Weight Loss Injections in South Africa: 2026 Buyer's Guide

Choosing between injectable weight-loss options in South Africa in 2026 comes down to this: only one GLP-1 (liraglutide/Saxenda) is SAHPRA-registered specifically for obesity, Ozempic and Mounjaro are registered for type 2 diabetes and used off-label for weight loss, Wegovy and retatrutide are not registered locally, and unregistered "research peptides" sold online for human use sit in a legal grey zone under the Medicines and Related Substances Act 101 of 1965 [1][5]. This is the first South Africa-focused, side-by-side comparison of FDA-approved GLP-1 injections versus research peptides across mechanism, evidence, SAHPRA status, dosing and ZAR pricing — so you can evaluate injectable peptides for weight loss on local rules rather than US-centric explainers.

Key Takeaways

• Only Saxenda (liraglutide) is SAHPRA-registered for obesity; Ozempic and Mounjaro are registered for type 2 diabetes and prescribed off-label for weight loss
• GLP-1 receptor agonists suppress appetite and slow stomach emptying — they do not burn fat directly
• Registered options cost R2,700–R4,000/month; research peptides cost R1,400–R2,300 per vial but lack regulatory oversight and post-market safety monitoring
• Retatrutide shows the largest weight-loss effect (−24.2% at 48 weeks in Phase 2) but is not yet approved anywhere and carries a smaller safety database than Phase 3 compounds
• Research peptides sold online sit in a legal grey zone and carry contamination and dosing risks flagged by the AMA

The Five Injectables at a Glance (SA, 2026)

Injection	SAHPRA status	Typical SA cost (2025 anchor)
Saxenda (liraglutide)	Registered for obesity [1]	~R3,000–R4,000/month [unverified]
Ozempic (semaglutide)	Registered for T2D; off-label for weight loss [1]	R2,700–R3,100/month [1]
Mounjaro (tirzepatide)	Registered for T2D only [1]	R3,500–R4,000/month [unverified]
Wegovy (semaglutide 2.4 mg)	Not registered [1]	Grey-market only
Retatrutide and research peptides	Not registered [8]	Unregulated

The Short Answer

"Weight loss injections" in South Africa cover two very different categories, and conflating them is how buyers get burned.

The first is approved GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) with large Phase 3 human trials and SAHPRA or FDA registration, marketed by Novo Nordisk (semaglutide, liraglutide) and Eli Lilly (tirzepatide, retatrutide). These compounds have been through rigorous clinical testing in thousands of patients, establishing both efficacy and a known safety profile [1][8]. The second is research peptides (ipamorelin, tesamorelin, retatrutide) sold online without SAHPRA approval for human use [3][8]. Research-grade material lacks the quality assurance and post-market surveillance that regulatory approval provides.

Only liraglutide (Saxenda) is SAHPRA-registered specifically for obesity in South Africa as of 2025 [1]. Ozempic and Mounjaro are registered for type 2 diabetes and prescribed off-label for weight loss because doctors can legally prescribe registered medicines for unapproved indications when they take clinical responsibility [1]. Retatrutide is still investigational, with Phase 2 data showing −24.2% mean body weight loss at 12 mg weekly over 48 weeks but no Phase 3 obesity label anywhere [8]. Those Phase 2 numbers are promising but represent a much smaller safety database than the Phase 3 trials behind semaglutide and tirzepatide.

Concern: Off-label prescribing of Ozempic and Mounjaro for weight loss means your doctor carries the medico-legal risk if complications arise, and medical aid may not cover the cost under weight-management benefits.

Quick Comparison

Category	Examples	Human Phase 3 evidence	SAHPRA status (2026)	Indicative ZAR/month (2025)
GLP-1 / dual agonist	Saxenda, Ozempic, Mounjaro/tirzepatide	Yes [1][8]	Registered (obesity or T2D) [1]	R2,700–R4,000 [1]
Research peptides	Ipamorelin, tesamorelin, retatrutide	Phase 2 only or none [8]	Not registered [3]	Grey market

Clenbuterol and yohimbine are not peptides. Clenbuterol is a beta-2 agonist and yohimbine is an alpha-2 antagonist. Both get lumped into "fat loss injection" marketing where they don't belong. Keep those three buckets separate before comparing price or dose.

Comparison Table: GLP-1s vs Research Peptides (2026)

Prices are indicative ZAR cash prices from 2025 reporting and listed retailers; confirm with the pharmacy before transacting.

Compound	Mechanism	FDA status (2026)	SAHPRA status (2026)	Typical adult dose	Published weight loss	Common side effects	ZAR / month (2025)
Semaglutide (Ozempic / Wegovy)	GLP-1 receptor agonist	Approved (T2D, obesity as Wegovy, CV risk reduction) [13]	Registered for T2D only; Wegovy not registered [1]	0.25 → 2.4 mg weekly SC	~14.9% at 68 weeks in STEP-1 (2021) [8]	Nausea, vomiting, constipation [1]	R2,700–R3,100 [1]
Tirzepatide (Mounjaro / Zepbound)	Dual GIP / GLP-1 agonist	Approved (T2D as Mounjaro, obesity as Zepbound) [14]	Registered for T2D; obesity off-label [1]	2.5 → 15 mg weekly SC	~20.9% at 72 weeks in SURMOUNT-1 (2022) [8]	Nausea, diarrhoea, decreased appetite [8]	R3,500–R4,000 [1]
Liraglutide (Saxenda)	GLP-1 receptor agonist	Approved (obesity, T2D as Victoza) [7]	Only GLP-1 registered for obesity in SA [1]	0.6 → 3.0 mg daily SC	~8% at 56 weeks (SCALE context) [7]	Nausea, injection-site reactions [1]	R3,000–R4,000 [1]
Retatrutide	Triple GLP-1 / GIP / glucagon agonist	Investigational, Phase 3 ongoing [8][10]	Not registered [3]	2–12 mg weekly SC (trial doses) [8]	−24.2% at 48 weeks, 12 mg (Phase 2, 2023) [8]	Nausea, vomiting, dose-dependent GI [8]	Grey market only
Tesamorelin	GHRH analogue (visceral fat)	Approved for HIV-lipodystrophy only [3]	Not registered for weight loss [3]	2 mg daily SC	Visceral fat reduction in HIV; no general obesity Phase 3 [3]	Injection-site reactions, joint pain [3]	Grey market only
Ipamorelin	Growth hormone secretagogue	Not approved for any indication [3]	Not registered [3]	No validated human obesity dose [3]	No published obesity Phase 3 data [3]	Unknown, contamination risk [3]	Grey market only

The top three rows are the only injectable peptides for weight loss with both Phase 3 evidence and a legal pharmacy route in South Africa. The bottom three lack SAHPRA registration, Phase 3 obesity data, or both [3][8].

How GLP-1 Injections Work (Semaglutide, Tirzepatide, Liraglutide)

GLP-1 receptor agonists cause weight loss by reducing how much you eat, not by burning fat. They mimic glucagon-like peptide-1 (GLP-1), a gut hormone released after meals, which slows gastric emptying, dampens hunger signals in the hypothalamus, and improves post-meal insulin response [1]. Food sits in the stomach longer, so you feel full sooner and the brain's appetite drive softens. Caloric deficit still does the work; the injection makes the deficit sustainable by suppressing hunger rather than by increasing energy expenditure.

Semaglutide (Ozempic, Wegovy)

Semaglutide is a once-weekly GLP-1 receptor agonist made by Novo Nordisk. The STEP-1 trial published in NEJM in 2021 reported mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo, underpinning the Wegovy weight-management label [8]. The SELECT cardiovascular outcomes trial later supported a March 2024 FDA label expansion for MACE (major adverse cardiovascular events) risk reduction in adults with overweight or obesity and established cardiovascular disease [12]. In South Africa, only Ozempic (0.25–1 mg pens for type 2 diabetes) is SAHPRA-registered as of early 2025; Wegovy is not [5]. Compounded semaglutide, which proliferated during US shortages, is not a SAHPRA-recognised route in South Africa and has been flagged by the AMA for dosing and contamination risk [1].

Concern: Wegovy's absence from the SAHPRA register means any local supply is grey-market. The cardiovascular benefit from SELECT applies only to the 2.4 mg dose used in that trial, not lower diabetes doses.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide, Eli Lilly's dual agonist, hits both the GLP-1 and the GIP (glucose-dependent insulinotropic polypeptide) receptors. The added GIP arm appears to enhance insulin sensitivity and amplify appetite suppression beyond GLP-1 alone, which is the working explanation for the larger weight-loss effect seen in SURMOUNT-1 (NEJM 2022) compared with STEP-1 [8]. The dual mechanism produces roughly 6 percentage points more weight loss than semaglutide at comparable timepoints. Dosing is weekly subcutaneous, titrated from 2.5 mg up to 15 mg. In SA, Mounjaro is SAHPRA-registered for type 2 diabetes only; obesity use is off-label [5]. For readers comparing pens directly, the Body Pharm Tirzepatide 30 Pen sits in this category.

Liraglutide (Saxenda, Victoza)

Liraglutide is the older, shorter-acting GLP-1 in the group, which is why Saxenda is injected daily rather than weekly [7]. Same mechanism: GLP-1 receptor agonism slowing gastric emptying and reducing hunger. The daily dosing requirement makes adherence harder than weekly alternatives, and the weight-loss effect is smaller (8% in SCALE trials versus 14.9% for semaglutide). Even so, Saxenda is the only GLP-1 SAHPRA-registered specifically for weight management in South Africa as of 2025 [5], which means a prescriber can write it for obesity without legal ambiguity.

Concern: Daily injections reduce adherence compared to weekly options, and the smaller weight-loss effect may disappoint buyers comparing it to tirzepatide or semaglutide.

None of this class melts fat. They make eating less feel sustainable, and the rest is arithmetic.

Research Peptides: Retatrutide, Tesamorelin, Ipamorelin

None of the peptides in this section are SAHPRA-registered for weight loss in South Africa, and selling them for human use without registration likely contravenes the Medicines and Related Substances Act 101 of 1965 [3][4]. They are sold online as "research-use-only" reagents — that is the loophole vendors rely on. Evidence quality varies considerably across the three, and none has FDA approval for weight loss as of 2026 [10].

Retatrutide

Retatrutide is a once-weekly triple agonist hitting GIP, GLP-1, and glucagon receptors, currently in Phase 3 development by Eli Lilly with no approval anywhere as of 2026 [8][12]. Adding the glucagon receptor arm to the GLP-1/GIP backbone is thought to drive higher energy expenditure on top of appetite suppression, which is the working explanation for the large Phase 2 numbers. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported a least-squares mean weight loss of −24.2% at 48 weeks on 12 mg weekly versus −2.1% on placebo, with 83% of participants hitting ≥15% loss and 93% hitting ≥10% [8]. Those are the largest figures seen in any GLP-1-class trial to date. Phase 2 results in roughly 300 people are not the same as a Phase 3 readout, and the safety database is still thin because fewer patients have been exposed for longer periods. Full Phase 3 primary endpoint data had not been peer-reviewed by late 2025 [12]. Anything labelled "retatrutide" for sale online in SA today is grey-market research material, not pharmaceutical-grade product with batch certification you can trust.

Concern: Phase 2 data alone cannot predict Phase 3 outcomes or long-term safety. Buying retatrutide now means accepting a much smaller evidence base than semaglutide or tirzepatide.

Tesamorelin

Tesamorelin is a synthetic growth-hormone-releasing hormone (GHRH) analogue, FDA-approved only for reducing excess visceral abdominal fat in HIV-associated lipodystrophy. The pivotal evidence is the Falutz et al. NEJM 2007 trial in HIV patients showing visceral adipose tissue reduction; no large randomised controlled trial establishes efficacy or safety for general weight loss in non-HIV adults. It is not SAHPRA-registered for obesity, and off-label use in cosmetic fat-loss clinics has no high-quality outcome data behind it. Prescribers have no evidence base for dosing or monitoring in non-HIV populations.

Ipamorelin

Ipamorelin is a selective growth hormone secretagogue with no published human weight-loss trial data and no approval in any major jurisdiction. The AMA's 2024 patient guidance specifically warns that injectable peptides sold for fat loss, including ipamorelin, often come from compounding or grey-market sources, lack FDA oversight, and carry contamination and dosing risks [1]. The same concerns apply locally because these vials sit entirely outside SAHPRA's quality assurance system [1][4]. Without regulatory oversight, there is no way to verify that a vial labelled "ipamorelin" actually contains ipamorelin at the stated concentration.

Concern: No clinical obesity data exists for tesamorelin or ipamorelin. Buying either means you are the experiment.

For a current inventory of what's available, browse the weight loss injections category to see what's in stock and at what dose.

Are These Injections Legal in South Africa? (SAHPRA Status 2026)

Of the injectables discussed in this guide, only three are SAHPRA-registered medicines in 2026: Ozempic (semaglutide, for type 2 diabetes), Saxenda (liraglutide, for weight management), and Mounjaro (tirzepatide, for type 2 diabetes) [5]. Wegovy, Zepbound, retatrutide, tesamorelin and ipamorelin are not SAHPRA-registered for any indication as of early 2026 [5][10].

SAHPRA (the South African Health Products Regulatory Authority) is the local equivalent of the FDA, but its registration list is much shorter and lags US/EU approvals by years because the regulator has fewer staff and a smaller budget. A medicine only becomes lawfully sellable for human use once SAHPRA has registered it and assigned it a schedule under the Medicines and Related Substances Act 101 of 1965 [3].

What's Registered and for What

Compound	Brand	SAHPRA-registered?	Indication on label
Semaglutide	Ozempic	Yes	Type 2 diabetes [5]
Semaglutide 2.4 mg	Wegovy	No (not registered in SA as of 2025) [5]	—
Liraglutide	Saxenda	Yes	Weight management (only GLP-1 registered for obesity in SA) [5]
Tirzepatide	Mounjaro	Yes	Type 2 diabetes; weight loss is off-label [5]
Tirzepatide	Zepbound	No	—
Tirzepatide (research)	Body Pharm Tirzepatide 30 Pen	No (research material)	—
Retatrutide	—	No (investigational, Phase 2/3) [10][12]	—
Tesamorelin, ipamorelin, AOD-9604	—	No	—

Using Ozempic or Mounjaro for weight loss is off-label prescribing, which is legal in SA when a registered doctor writes the script and takes clinical responsibility. Saxenda is the only on-label option for obesity [5].

Research Peptides: The Grey Zone

Vials of retatrutide, tesamorelin, ipamorelin and similar compounds are sold in SA as research chemicals, not medicines. That distinction matters legally because SAHPRA's quality oversight does not extend to research-only material. The AMA has flagged contamination and dosing risks specifically for grey-market peptide vials [1]. Selling or advertising these for human injection without registration would likely contravene the Medicines Act. The buyer carries the responsibility for what they do with the product once it leaves the shelf. The full weight loss injections category labels each item accordingly so you can see which bucket a product falls into before checkout.

Concern: Buying research peptides puts you outside the regulatory safety net. If something goes wrong, you have no recourse and your prescriber may refuse to treat you.

Typical Dosing Protocols (Adult Reference Ranges)

Every injectable in the weight loss injections category is titrated upward over weeks, not started at the target dose, to blunt nausea and GI side effects. The table below is reference material from published labels and trial protocols, not a prescription. Final dosing belongs to a registered SA prescriber who knows your history.

Compound	Starting dose	Target / max dose	Frequency	Route	Source
Semaglutide (Wegovy)	0.25 mg/week	2.4 mg/week	Weekly	SC	[13]
Semaglutide (Ozempic, off-label)	0.25 mg/week	1.0–2.0 mg/week	Weekly	SC	[5]
Tirzepatide (Zepbound/Mounjaro)	2.5 mg/week	15 mg/week	Weekly	SC	[14]
Liraglutide (Saxenda)	0.6 mg/day	3.0 mg/day	Daily	SC	[7]
Retatrutide (Phase 2 trial, 2023)	1 mg/week	up to 12 mg/week	Weekly	SC	[10]
Tesamorelin (Egrifta label)	2 mg/day	2 mg/day	Daily	SC	[unverified label dose]
Ipamorelin (research protocols)	200–300 mcg	200–300 mcg, 1–3x/day	Daily, non-clinical	SC	no clinical label exists

How the GLP-1 Titrations Actually Run

Semaglutide and tirzepatide step up roughly every four weeks because this interval lets the body adapt to each dose and allows nausea to settle before the next increase. Wegovy's published schedule moves 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16–20 weeks [13]. Tirzepatide's label runs 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg in 2.5 mg increments at four-week intervals, and most patients hold at 10 or 15 mg [14]. Saxenda is the outlier: daily injection, with weekly 0.6 mg increases until 3.0 mg [7]. The Body Pharm Tirzepatide 30 Pen is sold as research material and is not a substitute for a titration plan a doctor signs off on.

Retatrutide and the Research Peptides

Retatrutide's Phase 2 obesity trial (2023) used weekly doses of 1, 4, 8 and 12 mg, with the 12 mg arm producing −24.2% mean body-weight loss at 48 weeks versus −2.1% placebo [10]. Phase 3 dosing is still being finalised through Lilly's pipeline studies [12]. Tesamorelin has a real label (2 mg daily SC) but it was approved for HIV-associated lipodystrophy, not general fat loss. Ipamorelin has no clinical label at all. Numbers like 200–300 mcg one to three times daily come from bodybuilding and research-chemical forums, not regulator-reviewed studies, and the AMA has specifically warned against treating those protocols as established medicine [1]. A prescriber who will write and supervise the protocol is non-negotiable.

Concern: Self-dosing research peptides without a prescriber's oversight is the highest-risk scenario on this page.

Real-World Cost in ZAR: What You'll Actually Pay

The cheapest SAHPRA-registered option (Saxenda) runs roughly R2,500–R4,000/month at SA retail pharmacies in 2025, while research peptides sold for laboratory use start near R1,400 per 10 mg vial. Wegovy is not registered in SA as of early 2025 [1], so any "Wegovy" sold locally is a grey-market import without SAHPRA oversight.

Option	2026 indicative price (ZAR)	Format	SAHPRA status	Medical-aid reimbursement
Saxenda (liraglutide)	~R3,000–R4,000/month [unverified, 2024–2025]	Pre-filled pen	Registered for obesity [1]	Discovery Health may fund from day-to-day benefits, plan-dependent [1]
Ozempic (semaglutide 1 mg)	~R2,700–R3,100/month [2025] [1]	Pre-filled pen	Registered for T2D only; weight-loss use is off-label [1]	Generally only under diabetes benefits [4][5]
Mounjaro / Zepbound	No consistent SA retail price; imported [unverified]	Pen	Mounjaro registered for T2D, not obesity [1]	Diabetes benefits only [4][5]
HD Labs Semaglutide 10 mg	R1,400 (Beskinny 2026)	Research vial	Not registered; research use	None
HD Labs Retatrutide 10 mg	R1,600 sale (Beskinny 2026)	Research vial	Not registered; investigational [7][12]	None
HD Labs Retatrutide 32 mg	R2,300 (Beskinny 2026)	Research vial	Not registered; investigational	None
Body Pharm Tirzepatide 30 Pen	See current listing	Research pen	Not registered for obesity	None

Why the Price Gap Is Mostly a Regulatory Gap

A R1,400 research vial of semaglutide and an R2,700 Ozempic pen often contain the same active molecule. What you pay extra for at the pharmacy is SAHPRA registration, cold-chain logistics, a pharmacist's dispensing fee, and a prescriber who carries the medico-legal risk if something goes wrong. Strip those out and the price drops. So does the accountability. Browse the full weight loss injections category and compare line by line before deciding which trade-off you're buying.

Concern: Cheaper research peptides may seem like a bargain, but you lose regulatory oversight, post-market surveillance, and prescriber accountability.

Side Effects and Who Should Not Use Them

GLP-1 receptor agonists cause predictable gastrointestinal side effects and carry a boxed warning for thyroid C-cell tumours. Research peptides carry the same theoretical risks plus the unknown of an unregulated supply chain. Before you buy from the weight loss injections category, read this section and then ask a prescriber.

What Wegovy, Ozempic, Saxenda and Mounjaro Can Do to You

The most common adverse effects across semaglutide, liraglutide and tirzepatide are nausea, vomiting, diarrhoea and constipation, usually worst during dose escalation when the body is adjusting to a new hormone level. Less common but more serious risks listed on the Wegovy and Zepbound prescribing information include acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury from dehydration, and hypoglycaemia when combined with insulin or sulfonylureas [2][3]. Both semaglutide and tirzepatide carry a boxed warning against use in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on rodent C-cell tumour signals [2][3].

Do not use any GLP-1 if you are pregnant, planning pregnancy, breastfeeding, or have had pancreatitis. Tirzepatide can also reduce the efficacy of oral contraceptives, so a barrier method or non-oral contraceptive is advised for four weeks after starting and after each dose increase [3].

What's Different About Research Peptides

Research-grade semaglutide, tirzepatide and retatrutide share the same mechanism-based risks as the branded versions, with one extra problem: no post-marketing surveillance. The AMA flagged in 2024 that compounded and grey-market peptide injections have been linked to dosing errors, bacterial contamination, and unknown excipients, with no MedWatch-equivalent system catching adverse events [10]. Retatrutide itself only has Phase 2 safety data published so far, with full Phase 3 outcomes still pending [1][14].

If you are still considering a research vial like the Body Pharm Tirzepatide 30 Pen, get baseline bloods, screen for MTC/MEN2 family history, and work with a doctor who knows you are using it. Self-prescribing without medical oversight is the worst trade-off on this page.

Concern: Research peptides lack post-market safety monitoring. Adverse events go unreported, and you have no way to know if a batch is contaminated until you inject it.

How to Choose: A Decision Framework

The right injection depends on which constraint is hardest for you: medical risk, cost, or regulatory comfort. Use the table below as a starting filter, then take the three questions to your prescriber.

Your situation	Best-fit option	Why
Want the lowest-risk, evidence-backed route and can afford R2.7k–R3.1k/month [1]	SAHPRA-registered GLP-1 via prescriber (Ozempic off-label, or Saxenda for obesity) [1]	Registered supply chain, pharmacovigilance, prescriber accountability
Established cardiovascular disease + overweight/obesity	Semaglutide 2.4 mg pathway (note: Wegovy not yet SAHPRA-registered as of 2025) [1][9]	SELECT trial (2023) showed ~20% MACE reduction over ~5 years [9]
Type 2 diabetes alongside weight goal	Ozempic or Mounjaro through medical aid diabetes benefit [1]	Both SAHPRA-registered for T2D; may be funded under chronic benefits
BMI ≥35 with T2D considering dual agonism	Tirzepatide (Mounjaro) off-label under specialist supervision [1]	SURMOUNT-1 (2022) showed ~20.9% weight loss at 72 weeks [8]
Cost is the binding constraint	Discuss compounded or alternative regimens with a doctor who will monitor you	Self-sourcing without supervision is the worst trade-off
Pregnant, planning pregnancy, breastfeeding, or prior pancreatitis	None of the above	Contraindicated [2][3]

Research-grade vials from the weight loss injections category, including the Body Pharm Tirzepatide 30 Pen, are sold for research use and are not a clinical substitute for a SAHPRA-registered prescription.

Three Questions to Ask Your Prescriber

1. Will my medical aid cover this, and under which benefit (chronic, day-to-day, or not at all)? Discovery Health has confirmed Saxenda is funded only from day-to-day benefits, not as a PMB [1].
2. What is the titration plan, and what dose are we targeting by month four?
3. What is the exit strategy after 12 months? Do we taper, switch, or maintain, and how do we manage likely weight regain?

FAQ: Weight Loss Injections in South Africa

Question	Short answer
Which weight loss injections are FDA-approved in 2026?	Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda, Victoza). Retatrutide is investigational [10][13][14].
Do peptides burn fat directly?	No. GLP-1s suppress appetite and slow gastric emptying; they don't oxidise fat tissue [1].
Is retatrutide approved in SA?	No. Phase 2 data only as of 2023; no SAHPRA registration and no FDA approval as of 2026 [7][10].
Are clenbuterol and yohimbine peptides?	No. Clenbuterol is a beta-2 agonist, yohimbine is an alpha-2 antagonist. Neither belongs in the peptide category.
How fast does semaglutide work?	Appetite drops within 1–2 weeks; meaningful weight loss usually shows after 8–12 weeks of titration [5].
Does medical aid cover it?	Discovery Health funds Saxenda from day-to-day benefits, not PMB. Ozempic and Mounjaro for weight loss are generally not covered [5].
What happens when you stop?	Significant weight regain is common within 12 months without a maintenance plan [1].

Can You Stack GLP-1s with Clenbuterol or Other Stimulants?

Don't. Clenbuterol is not registered for human use in South Africa, and stacking a beta-2 agonist with a GLP-1 compounds cardiovascular risk, including arrhythmia and tachycardia. No clinical trial supports the combination, and prescribers I've spoken to in 2025 refuse to monitor it.

Are Oral GLP-1 Alternatives Available in SA?

Oral semaglutide (Rybelsus) is registered globally for type 2 diabetes, but uptake in South Africa lags injectables on cost and dosing convenience. For obesity specifically, no oral GLP-1 has SAHPRA approval as of 2025 [5].

How Does Retatrutide Compare to Semaglutide on Weight Loss?

In Lilly's Phase 2 obesity trial (Jastreboff et al., NEJM 2023), 12 mg weekly retatrutide produced −24.2% mean body weight loss at 48 weeks versus −2.1% on placebo, with 83% of participants hitting ≥15% loss [7]. That outperforms STEP-1's 14.9% semaglutide 2.4 mg average at 68 weeks. Phase 3 confirmation and SAHPRA registration are still pending.

Is Buying Research-Grade Tirzepatide Legal for Personal Use?

Vials in the weight loss injections category, including the Body Pharm Tirzepatide 30 Pen, are sold for research purposes. They are not SAHPRA-registered medicines, and marketing them for human administration would likely contravene the Medicines and Related Substances Act 101 of 1965 [3][4].

Will the SELECT Cardiovascular Benefit Apply if I Use Ozempic Off-Label?

The 20% MACE reduction came from semaglutide 2.4 mg (Wegovy) in people with overweight/obesity and established CVD, over ~5 years in SELECT (2023) [13]. Ozempic tops out at 1 mg or 2 mg for diabetes dosing. Extrapolating the CV benefit to lower doses or shorter use is not supported by the trial data.

Which Weight Loss Injection Should I Choose?

If you have T2D and weight to lose, Ozempic or Mounjaro via your medical aid's diabetes benefit is the cleanest path. If you have obesity without diabetes and want an on-label SAHPRA-registered option, Saxenda is currently the only one. If you have established cardiovascular disease, the semaglutide 2.4 mg pathway has the strongest outcome data, but you'll need to navigate Wegovy's unregistered status with your prescriber. Anything else is a regulatory and supply-chain trade-off you should make with eyes open.

Next Steps

Book a 20-minute consult with a SAHPRA-registered prescriber, confirm your medical aid benefit category in writing, and only then compare current listings in the weight loss injections category. A prescriber who knows your full medical history and is willing to monitor you is the non-negotiable first step.